PT1239831E - Composições farmacêuticas melhoradas para fármacos fracamente solúveis - Google Patents
Composições farmacêuticas melhoradas para fármacos fracamente solúveisInfo
- Publication number
- PT1239831E PT1239831E PT986890T PT00986890T PT1239831E PT 1239831 E PT1239831 E PT 1239831E PT 986890 T PT986890 T PT 986890T PT 00986890 T PT00986890 T PT 00986890T PT 1239831 E PT1239831 E PT 1239831E
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutical compositions
- poorly soluble
- soluble drugs
- improved pharmaceutical
- improved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ4854A AUPQ485499A0 (en) | 1999-12-23 | 1999-12-23 | Improved pharmaceutical compositions for poorly soluble drugs |
AUPQ7450A AUPQ745000A0 (en) | 2000-05-12 | 2000-05-12 | Improved pharmaceutical compositions for poorly soluble drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1239831E true PT1239831E (pt) | 2013-01-23 |
Family
ID=25646230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT986890T PT1239831E (pt) | 1999-12-23 | 2000-12-22 | Composições farmacêuticas melhoradas para fármacos fracamente solúveis |
Country Status (8)
Country | Link |
---|---|
US (3) | US20030086976A1 (pt) |
EP (2) | EP2415462A1 (pt) |
JP (2) | JP5159012B2 (pt) |
AU (2) | AU2331801A (pt) |
CA (1) | CA2396380C (pt) |
ES (1) | ES2398643T3 (pt) |
PT (1) | PT1239831E (pt) |
WO (1) | WO2001047492A1 (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
EP2415462A1 (en) * | 1999-12-23 | 2012-02-08 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
GB0012448D0 (en) | 2000-05-24 | 2000-07-12 | Astrazeneca Ab | New process |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
GB0015239D0 (en) * | 2000-06-21 | 2000-08-16 | Biochemie Gmbh | Organic compounds |
GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
EP1401399A2 (en) * | 2001-06-22 | 2004-03-31 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
MXPA04007433A (es) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado. |
ATE359777T1 (de) * | 2002-12-17 | 2007-05-15 | Abbott Gmbh & Co Kg | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate |
US20080051411A1 (en) * | 2002-12-17 | 2008-02-28 | Cink Russell D | Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
US20080152714A1 (en) * | 2005-04-08 | 2008-06-26 | Yi Gao | Pharmaceutical Formulations |
JP2007308480A (ja) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 腸溶性固体分散体を含んでなる固形製剤 |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
AU2007265452A1 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
US8946200B2 (en) * | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
ES2496166T3 (es) * | 2006-12-22 | 2014-09-18 | Yuhan Corporation | Dispersión sólida que contiene revaprazán y proceso para la preparación de la misma |
EP2134327A1 (en) * | 2007-03-13 | 2009-12-23 | Sandoz AG | Pharmaceutical compositions of poorly soluble drugs |
US8404850B2 (en) * | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
EP2257220B1 (en) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Multi-function, foot-activated controller for imaging system |
PE20091778A1 (es) * | 2008-04-15 | 2009-11-13 | Schering Corp | Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden |
CA2720851A1 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | Oral pharmaceutical compositions in a molecular solid dispersion |
US8722706B2 (en) * | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
US8309134B2 (en) * | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
US9028873B2 (en) * | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CN105708819B (zh) * | 2011-11-23 | 2020-12-29 | 诺华股份有限公司 | 医药制剂 |
US9650851B2 (en) | 2012-06-18 | 2017-05-16 | Schlumberger Technology Corporation | Autonomous untethered well object |
EP2863911A4 (en) | 2012-06-21 | 2016-07-13 | Mayne Pharma Int Pty Ltd | ITRACONAZOLE COMPOSITIONS AND METHOD OF DOSING AND METHOD OF USE THEREOF |
US9192609B2 (en) * | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
CN104644557B (zh) * | 2013-11-22 | 2017-10-31 | 上海宣泰医药科技有限公司 | 卟啉铁固体分散体及其制备方法 |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
JP2020506905A (ja) * | 2017-01-20 | 2020-03-05 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. | (r)−n−((4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロピリジン−3−イル)メチル)−2−メチル−1−(1−(1−(2,2,2−トリフルオロエチル)ピペリジン−4−イル)エチル)−1h−インドール−3−カルボキサミド固体分散液 |
CA3073228A1 (en) | 2017-08-20 | 2019-02-28 | University Of Connecticut | Azole analogues and methods of use thereof |
WO2020159562A1 (en) | 2019-01-29 | 2020-08-06 | Slayback Pharma Llc | Pharmaceutical compositions of posaconazole |
US11318107B2 (en) | 2019-02-22 | 2022-05-03 | Avior, Inc. | Pharmaceutical active-containing film delivery device for oral transmucosal administration |
KR20220088683A (ko) * | 2019-08-28 | 2022-06-28 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 치다미드 제약 조성물, 이의 제조 방법 및 이의 용도 |
US20210346506A1 (en) | 2020-05-07 | 2021-11-11 | Guibai Liang | Prodrug of itraconazole and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02167219A (ja) * | 1988-12-20 | 1990-06-27 | Fujisawa Pharmaceut Co Ltd | 固体分散体の製造方法 |
JP3110794B2 (ja) | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | 1,4−ジヒドロピリジン誘導体を含有する製剤 |
US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
WO1997004782A1 (fr) * | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Dispersion solide ou preparation a dispersion solide de derives xanthine |
NZ330739A (en) * | 1996-05-20 | 1999-06-29 | Janssen Pharmaceutica Nv | Particulate solid dispersion of itraconazole and a water soluble polymer |
AU3483497A (en) * | 1996-06-28 | 1998-01-21 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
DK0901786T3 (da) * | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
DE69808670T2 (de) * | 1997-12-31 | 2003-07-03 | Choongwae Pharma Corp | Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol |
KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
DE19843904A1 (de) * | 1998-09-24 | 2000-03-30 | Basf Ag | Feste Dosierungsform mit polymerem Bindemittel |
WO2000040220A1 (en) * | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
EP2415462A1 (en) * | 1999-12-23 | 2012-02-08 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
-
2000
- 2000-12-22 EP EP20110187961 patent/EP2415462A1/en not_active Withdrawn
- 2000-12-22 WO PCT/AU2000/001592 patent/WO2001047492A1/en active Application Filing
- 2000-12-22 AU AU23318/01A patent/AU2331801A/en not_active Abandoned
- 2000-12-22 JP JP2001548087A patent/JP5159012B2/ja not_active Expired - Fee Related
- 2000-12-22 CA CA2396380A patent/CA2396380C/en not_active Expired - Lifetime
- 2000-12-22 EP EP00986890A patent/EP1239831B1/en not_active Expired - Lifetime
- 2000-12-22 ES ES00986890T patent/ES2398643T3/es not_active Expired - Lifetime
- 2000-12-22 PT PT986890T patent/PT1239831E/pt unknown
- 2000-12-22 AU AU72529/00A patent/AU782469B2/en not_active Expired
-
2002
- 2002-06-21 US US10/175,883 patent/US20030086976A1/en not_active Abandoned
-
2003
- 2003-06-16 US US10/461,503 patent/US6881745B2/en not_active Expired - Lifetime
-
2007
- 2007-06-15 US US11/763,578 patent/US8771739B2/en not_active Expired - Lifetime
-
2012
- 2012-07-17 JP JP2012158751A patent/JP2012236837A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2012236837A (ja) | 2012-12-06 |
ES2398643T3 (es) | 2013-03-20 |
US6881745B2 (en) | 2005-04-19 |
US20030086976A1 (en) | 2003-05-08 |
AU7252900A (en) | 2001-06-28 |
AU2331801A (en) | 2001-07-09 |
US20030225104A1 (en) | 2003-12-04 |
US20080260835A1 (en) | 2008-10-23 |
CA2396380A1 (en) | 2001-07-05 |
CA2396380C (en) | 2015-04-21 |
AU782469B2 (en) | 2005-08-04 |
EP1239831A1 (en) | 2002-09-18 |
JP2003518483A (ja) | 2003-06-10 |
WO2001047492A1 (en) | 2001-07-05 |
EP1239831A4 (en) | 2009-07-22 |
EP1239831B1 (en) | 2012-10-31 |
JP5159012B2 (ja) | 2013-03-06 |
US8771739B2 (en) | 2014-07-08 |
EP2415462A1 (en) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1239831E (pt) | Composições farmacêuticas melhoradas para fármacos fracamente solúveis | |
HUP0204372A3 (en) | Pharmaceutical compositions providing enhanced drug concentrations | |
HUP0202513A2 (en) | Betha-carboline pharmaceutical compositions | |
GB0028088D0 (en) | Pharmaceutical compositions | |
GB0001662D0 (en) | Pharmaceutical compositions | |
GB9923436D0 (en) | Pharmaceutical compositions | |
IL145559A0 (en) | Tolperison-containing pharmaceutical preparation for oral administration | |
EP1221926A4 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING MEDICINAL SUBSTANCES WITH LOW SOLUBILITY | |
GB9904163D0 (en) | Pharmaceutical compositions | |
HK1046140A1 (zh) | 固體藥劑 | |
GB9911017D0 (en) | Pharmaceutical compositions | |
HK1045102A1 (zh) | 藥物配方 | |
GB9909154D0 (en) | Pharmaceutical formulation | |
GB9904911D0 (en) | Pharmaceutical compositions | |
IL149470A0 (en) | Pharmaceutical compositions containing carboxamidoadenosine derivatives | |
EP1221941A4 (en) | PHARMACEUTICAL FORMULATIONS POWDER | |
GB9906126D0 (en) | Pharmaceutical formulations | |
GB9930578D0 (en) | Pharmaceutical formulations | |
GB9926251D0 (en) | Pharmaceutical formulation | |
GB9902651D0 (en) | Pharmaceutical compositions | |
AUPQ485499A0 (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
AUPQ745000A0 (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
GB9903177D0 (en) | Pharmaceutical formulations | |
GB9905983D0 (en) | Pharmaceutical formulations | |
GB9911826D0 (en) | Pharmaceutical formulations |